---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-111170"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-09-28T12:16:10+00:00"
generated_at: "2026-10-12T13:31:14.087494+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TransCode's TTX-MC138 shows 71.4% stable disease in Phase 1a; no dose-limiting toxicities

## Summary
- 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as best overall response by investigator assessment; disease control was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1.
- Durability: 6 of 14 patients progression-free at 3 months, 3 at 6, 9 and 12 months; three efficacy-evaluable patients remain progression-free at one year.
- No dose-limiting toxicities at any dose including the highest evaluated 4.8 mg/kg; 98 doses administered as of the September 1, 2026 data cutoff; no treatment discontinuations.
- Post-hoc Growth Modulation Index: 6 of 15 evaluable patients (40%) had GMI above 1.3, meaning at least 30% longer progression-free interval than their prior therapy.
- Exploratory blood RNA-sequencing showed dose-dependent antitumor immune activation; TransCode is evaluating dose-expansion strategies in selected cancers and molecularly defined populations.

## SEC filing metadata
- accession: 0001104659-26-111170
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-09-28T12:16:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926111170/0001104659-26-111170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926111170/tm2626237d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-111170
- JSON: https://secwatch.observer/filing/0001104659-26-111170.json
- Plain text: https://secwatch.observer/filing/0001104659-26-111170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.